文献速递肝病

质子泵抑制剂的启用与停用影响肝硬化患者肠道菌群及再入院风险

Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis.
PubMed 文献 · Am J Gastroenterol · 2018-06-06

本研究纳入四个队列,探讨质子泵抑制剂(PPI)使用、启用及停用对肝硬化患者肠道菌群和再入院的影响。再入院研究中343例住院患者中21例停用、45例启用PPI,PPI使用增加21%,PPI与30天(p=0.002)和90天(p=0.008)再入院风险升高相关;横断面菌群研究中,使用PPI者口腔来源菌群增多,肝硬化使用PPI者固有菌群减少;纵向研究中,15例失代偿期肝硬化患者耐受奥美拉唑启用且口腔来源菌群较基线增加,另15例停用PPI后口腔来源菌群较基线显著减少。结论认为PPI调节肝硬化再入院风险和菌群组成,菌群对停用有反应,失代偿期肝硬化需系统性停用和审慎使用PPI。

要点

  • 肝硬化住院患者中PPI使用与30天(p=0.002)和90天(p=0.008)再入院风险升高相关,独立于合并症、药物、MELD和年龄。
  • 使用PPI者(无论有无肝硬化)口腔来源菌群增多,肝硬化使用PPI者固有菌群较其余人群减少。
  • 15例失代偿期肝硬化患者耐受奥美拉唑启用,口腔来源菌群较基线增加;另15例停用PPI后口腔来源菌群较基线显著减少。

核心结论

  • PPI调节肝硬化患者再入院风险和肠道菌群组成,菌群对PPI停用有反应。
  • 从临床和微生物学角度,失代偿期肝硬化需要系统性停用和审慎使用PPI。

研究设计与样本

  • 再入院研究:肝硬化住院患者住院期间及出院后30天和90天随访,分析有或无再入院者之间PPI启用、停用/继续使用的模式。
  • 横断面菌群研究:肝硬化门诊患者和对照者接受粪便菌群分析,分析有益固有菌群和口腔来源菌群与PPI使用的关系。
  • 纵向研究:两个失代偿期肝硬化门诊患者队列,长期无指征使用PPI者停用14天,未使用PPI者启用奥美拉唑14天,干预前后进行口腔来源菌群分析。

主要发现

  • 再入院研究纳入343例住院患者(151例入院时使用PPI),21例停用PPI、45例启用PPI,PPI使用增加21%。
  • PPI与30天再入院(p=0.002)和90天再入院(p=0.008)风险升高相关,独立于合并症、药物、MELD和年龄。
  • 横断面菌群研究纳入137例肝硬化患者(59例使用PPI)和45例对照者(17例使用PPI),使用PPI者无论有无肝硬化口腔来源菌群均较高,肝硬化使用PPI者固有菌群较其余人群减少。
  • 纵向研究中15例失代偿期肝硬化患者耐受奥美拉唑启用,口腔来源菌群较基线增加。
  • 另15例门诊患者停用PPI后口腔来源菌群较基线显著减少。

关键数值与推荐

  • 再入院研究样本为343例肝硬化住院患者,其中151例入院时使用PPI。
  • PPI与30天再入院相关(p=0.002),与90天再入院相关(p=0.008)。
  • 横断面菌群研究样本为137例肝硬化患者(59例使用PPI)和45例对照者(17例使用PPI)。
  • 纵向研究中奥美拉唑启用和PPI停用的干预时长均为14天,各15例。

临床怎么用

  • 原文结论认为从临床和微生物学角度,失代偿期肝硬化需要系统性停用和审慎使用PPI。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cirrhosis is associated with gut microbial dysbiosis, high readmissions and proton pump inhibitor (PPI) overuse, which could be inter-linked. Our aim was to determine the effect of PPI use, initiation and withdrawl on gut microbiota and readmissions in cirrhosis. METHODS: Four cohorts were enrolled. Readmissions study: Cirrhotic inpatients were followed throughout the hospitalization and 30/90-days post-discharge. PPI initiation, withdrawal/continuation patterns were analyzed between those with/without readmissions. Cross-sectional microbiota study: Cirrhotic outpatients and controls underwent stool microbiota analysis. Beneficial autochthonous and oral-origin taxa analysis vis-à-vis PPI use was performed. Longitudinal studies: Two cohorts of decompensated cirrhotic outpatients were enrolled. Patients on chronic unindicated PPI use were withdrawn for 14 days. Patients not on PPI were started on omeprazole for 14 days. Microbial analysis for oral-origin taxa was performed pre/post-intervention. RESULTS: Readmissions study: 343 inpatients (151 on admission PPI) were enrolled. 21 were withdrawn and 45 were initiated on PPI resulting in a PPI use increase of 21%. PPIs were associated with higher 30 (p = 0.002) and 90-day readmissions (p = 0.008) independent of comorbidities, medications, MELD and age. Cross-sectional microbiota: 137 cirrhotics (59 on PPI) and 45 controls (17 on PPI) were included. PPI users regardless of cirrhosis had higher oral-origin microbiota while cirrhotics on PPI had lower autochthonous taxa compared to the rest. Longitudinal studies: Fifteen decompensated cirrhotics tolerated omeprazole initiation with an increase in oral-origin microbial taxa compared to baseline. PPIs were withdrawn from an additional 15 outpatients, which resulted in a significant reduction of oral-origin taxa compared to baseline. CONCLUSIONS: PPIs modulate readmission risk and microbiota composition in cirrhosis, which responds to withdrawal. The systematic withdrawal and judicious use of PPIs is needed from a clinical and microbiological perspective in decompensated cirrhosis.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Bajaj JS, Acharya C, Fagan A, et al. Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis. Am J Gastroenterol. 2018. PMID: 29872220. doi:10.1038/s41395-018-0085-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。